搜尋
Beigene Ltd
ONC添加自選
315.970USD
-6.110-1.90%
收盤 07-31 16:00（美東）報價延遲15分鐘
32.31B總市值
67.69本益比TTM
關於 Beigene Ltd 公司
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Beigene Ltd簡介
公司代碼ONC
公司名稱Beigene Ltd
上市日期Mar 02, 2016
CEOOyler (John Victor)
員工數量11000
證券類型Depository Receipt
年結日Mar 02
公司地址c/o BeOne Medicines I GmbH
城市BASEL
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Switzerland
郵編4051
電話41616851900
網址https://beonemedicines.com/
公司代碼ONC
上市日期Mar 02, 2016
CEOOyler (John Victor)
Beigene Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
11.61K
-41.00%
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Eric E. Hedrick, M.D.
Dr. Eric E. Hedrick, M.D.
Interim Chief Medical Officer, Immuno-Oncology
Interim Chief Medical Officer, Immuno-Oncology
--
--
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
11.61K
-41.00%
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
常見問題
Beigene Ltd的前五大股東是誰？
Beigene Ltd的前五大股東如下：Dr. Xiaobin Wu, Ph.D.
有多少機構持有Beigene Ltd(ONC)的股份？
截至2026Q1，共有602家機構持有Beigene Ltd的股份，合計持有的股份價值約為40.42M，占公司總股份的36.84% 。與2025Q4相比，機構持股有所增加，增幅為1961186.00。
哪個業務部門對Beigene Ltd的收入貢獻最大？
在2026Q1，Product業務部門對Beigene Ltd的收入貢獻最大，創收1.37B，占總收入的97.35% 。